Every Form 4 that AEON Biopharma, Inc. (AEON) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AEON and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AEON filings page.
AEON Biopharma, Inc. (AEON) reported that ten percent owner Timothy P. Lynch purchased 1,150,000 shares of Class A Common Stock on August 19, 2026. The weighted average purchase price was $0.2117 per share, with individual trades ranging from $0.1975 to $0.2164. Following this open-market purchase, Lynch directly owns 6,500,000 shares of AEON Class A Common Stock.
Thunen Shelley B reported acquisition or exercise transactions in this Form 4 filing.
AEON Biopharma director Shelley B. Thunen received an equity grant of 222,684 shares of Class A common stock in the form of restricted stock units. The award was granted on June 17, 2026 as compensation, at a grant price of $0.00 per share rather than an open-market purchase.
The RSUs vest in full on the earlier of the one-year anniversary of the grant date or the date of AEON Biopharma’s 2027 annual stockholder meeting, subject to her continued service. Following this award, Thunen directly holds 258,705 shares of the company’s Class A common stock.
PALMISANO ROBERT J reported acquisition or exercise transactions in this Form 4 filing.
AEON Biopharma director Robert J. Palmisano received an award of 222,684 restricted stock units (RSUs) of Class A Common Stock on June 17, 2026. The RSUs vest in full on the earlier of the one-year anniversary of the grant date or the 2027 annual stockholders’ meeting, subject to continued service. Following this grant, his direct holdings total 258,705 shares.
Forth Marc reported acquisition or exercise transactions in this Form 4 filing.
AEON Biopharma director Marc Forth reported an equity award of 222,684 shares of Class A Common Stock in the form of restricted stock units (RSUs). The RSUs were granted on June 17, 2026 at no cash price and represent compensation rather than an open-market purchase.
The RSUs vest in full on the earlier of the one-year anniversary of the June 17, 2026 grant date or the date of the company’s 2027 annual meeting of stockholders, subject to his continued service. Following this award, Forth directly holds 973,231 shares of AEON Biopharma common stock.
FISCHER JOST reported acquisition or exercise transactions in this Form 4 filing.
AEON Biopharma director Jost Fischer received an equity grant in the form of restricted stock units. The award covers 222,684 RSUs granted on June 17, 2026 at no cash cost, increasing his direct holdings to 489,469 shares of Class A Common Stock.
The RSUs vest in full on the earlier of the one-year anniversary of the grant date or the date of AEON Biopharma’s 2027 annual meeting of stockholders, conditioned on his continued service through the applicable vesting date. This is a compensation-related grant rather than an open‑market share purchase.
Carter Eric G reported acquisition or exercise transactions in this Form 4 filing.
AEON Biopharma director Eric G. Carter received an equity grant of 222,684 restricted stock units (RSUs) of Class A Common Stock. The award was granted on June 17, 2026 and carries no purchase price. The RSUs vest in full on the earlier of one year after the grant date or the 2027 annual stockholder meeting, subject to his continued service. Following this grant, Carter holds 258,705 shares directly.
Bencich John reported acquisition or exercise transactions in this Form 4 filing.
AEON Biopharma, Inc. reported that Chief Financial Officer John Bencich received a grant of 754,717 shares of Class A common stock in the form of restricted stock units. The award was granted on April 1, 2026 and carries no purchase price per share.
The restricted stock units vest in substantially equal installments on each of the first, second, third and fourth anniversaries of the grant date, contingent on continued service through each vesting date. Following this award, Bencich is shown as directly owning 754,717 shares of Class A common stock.
AEON Biopharma, Inc. chief medical officer Chad Oh reported receiving equity awards of Class A common stock as compensation. On February 17, 2026, he was granted 862,500 restricted stock units that vest in four substantially equal annual installments, starting on the first anniversary of the grant date, subject to continued service.
On March 4, 2026, 1,316,872 previously cash-settled restricted stock units granted on May 21, 2025 were modified to be settled in stock instead of cash upon vesting, while keeping the same four-year vesting schedule from the 2025 grant date. After these awards, his direct holdings increased to 2,183,436 shares of Class A common stock. These are compensation-related acquisitions, not open-market purchases or sales.
AEON Biopharma, Inc. reported that executive Wilson Alexander Blair, its CLO, CSO and Corporate Secretary, acquired Class A common stock through equity compensation awards rather than open-market purchases.
On February 17, 2026, he received an award of 862,500 restricted stock units, vesting in substantially equal installments on each of the first four anniversaries of the grant date, subject to continued service. On March 4, 2026, 1,316,872 previously cash-settled restricted stock units granted on May 21, 2025 were modified to be settled in stock instead of cash, with the original four-year vesting schedule maintained. Both transactions were reported at a price of $0.00 per share and are classified as direct ownership, bringing Blair’s total directly held Class A shares to 2,183,005 after the March 4 transaction.
AEON Biopharma, Inc. reported that its principal accounting officer, Jennifer Sy, acquired Class A common stock through equity awards. On February 17, 2026, she received an award of 575,000 restricted stock units that vest in substantially equal installments over four years, subject to continued service. On March 4, 2026, 925,925 previously granted cash-settled restricted stock units from May 21, 2025 were modified to be settled in stock instead of cash, while retaining the same four-year vesting schedule.
Bancroft Robert E. reported acquisition or exercise transactions in this Form 4 filing.
AEON Biopharma, Inc. reported that President and CEO Robert E. Bancroft received a grant of 3,000,000 shares of Class A Common Stock in the form of restricted stock units on February 17, 2026. The award was granted at a price of $0.00 per share.
These restricted stock units vest in substantially equal installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to his continued service. Following this award, his directly held Class A Common Stock stake reported in this filing is 3,177,103 shares.